Long Ideas - Data from the Closest Competition, It Turns Out, Support Sarepta Accelerated approval aside, the chatter regarding Sarepta Therapeutics (SRPT) in the past week has centered … Continue Reading
Read nowLong Ideas - PropThink will host an expert interview on Thursday, April 11 (details below) to discuss the intellectual property (IP) position on Zerenex, Keryx Biopharmaceutical’s (KERX) late-stage phosphate … Continue Reading
Read nowLong Ideas - Navidea Biopharmaceuticals (NAVB) delivered a surprise to investors with earlier-than expected top-line interim results from the company’s NEO3-06 trial, which demonstrated Lymphoseek’s ability to identify … Continue Reading
Read nowLong Ideas - The spotlight has been on Astex Pharmaceuticals (ASTX) in the last month, and as investors have taken notice of the oncology developer, shares have rallied … Continue Reading
Read nowLong Ideas - As we wrote last week, Endo Health’s (ENDP) newly appointed CEO and former Valeant (VRX) operating star Rajiv De Silva is on the road with … Continue Reading
Read nowLong Ideas - Acquiring non-dilutive capital is always encouraging for a development-stage biotech company, and investors should take note when a company improves its balance sheet without hurting … Continue Reading
Read nowMost Popular - Shares of Cadence Pharmaceuticals (CADX) have run too high too fast, and although fundamentals have improved significantly in the last year, we believe the stock … Continue Reading
Read now